Should You Buy TransMedics Group, Inc. Stock in 2026?
According to the CirclFi Deep Alpha Valuation Engine, TransMedics Group, Inc. (TMDX) ranks in the top tier of our coverage universe with a Quality of Company score of 9.2/10. Trading at a market price of $88.09, this high-quality profile requires careful comparison against our 13 intrinsic value models.
The short answer: 0 of 9 CirclFi valuation models project upside for TransMedics Group, Inc. (TMDX) at $88.09 — the model consensus leans bearish, with a Quality Score of 9.2/10 and Value-Trap risk of 6/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.
What Is the Investment Case for TransMedics Group, Inc. (TMDX) in 2026?
What Is the Bull Case vs the Bear Case for TransMedics Group, Inc. (TMDX)?
| Bull case | Bear case — $12.46 target (-85.9%) |
|---|---|
| No active model projects meaningful upside for TMDX at $88.09. Bulls would have to argue that qualitative factors the models cannot measure will unlock value. | According to the CirclFi Deep Alpha Valuation Engine, the RCMH-DCF model sees the stock as overvalued with a fair value of $12.46 (-85.9%), suggesting that the market price embeds overly optimistic growth assumptions. |
| According to the CirclFi Deep Alpha Valuation Engine, model disagreement is high with a +77.4% spread between the most bullish and bearish models, signaling elevated analytical uncertainty. | |
| Industry headwind: regulatory rejection risk represents a meaningful risk for TransMedics Group, Inc. and its Medical Devices peers. |
How Does TMDX Compare to Its Medical Devices Peers?
Valuation data pages: UFPT · ELMD · DXCM · SYK · GMED · INSP · KIDS · CBLL · VVOS · IRMD · PODD
Which Other Stocks Score Like TMDX on Quality?
Closest companies to TMDX’s Quality of Company score of 9.2/10, across all industries.
- HALO — Halozyme Therapeutics, Inc. (QOC 9.2) · analysis
- ALL — The Allstate Corporation (QOC 9.2) · analysis
- YMM — Full Truck Alliance Co. Ltd. (QOC 9.2) · analysis
- ESP — Espey Mfg. & Electronics Corp. (QOC 9.2) · analysis
- FTDR — Frontdoor, Inc. (QOC 9.2) · analysis
- NVDA — NVIDIA Corporation (QOC 10.0) · analysis
Which Medical Devices Screens Does TMDX Appear In?
So Is TransMedics Group, Inc. (TMDX) Worth Buying in 2026?
Our valuation engine sends a clear cautionary signal on TransMedics Group, Inc. at $88.09. 9/9 models flag overvaluation, median fair value sits at $40.28 (-54.3%), and the risk-reward profile appears unfavorable. Quality at 9.2/10 is the one bright spot, but premium quality at the wrong price can still destroy returns. This is a stock where patience — or avoidance — may be the optimal strategy.
These are quantitative model outputs, not investment recommendations. TransMedics Group, Inc.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →
What Else Do Investors Ask About TMDX Stock?
Should I buy TMDX stock right now?
Based on CirclFi's multi-model analysis, 0 of 9 models see upside for TMDX at $88.09. No active models currently project upside, suggesting the market price may already reflect or exceed fair value. This is not a buy recommendation — see our full disclaimer.
What are the biggest risks of investing in TransMedics Group, Inc.?
Key risks include: wide model disagreement (547% spread), signaling high uncertainty; general market and sector-specific risks affecting Medical Devices companies. Always diversify and consult a financial advisor.
How does TMDX compare to its competitors?
Among Medical Devices peers, TMDX holds a Quality Score of 9.2/10. Comparable companies include UFPT (QOC 9.2), ELMD (QOC 9.1), DXCM (QOC 9.2). The relative ranking helps investors identify whether TMDX offers better fundamental quality than alternatives in the same sector.
Is TMDX a good long-term investment?
Long-term investment potential depends on fundamental quality and sustainable competitive advantages. TMDX's Quality Score of 9.2/10 is encouraging for long-term holders, indicating consistent profitability, manageable debt, and healthy cash flows. Check our full data page for all 13 model estimates.
What price should I buy TMDX at?
CirclFi does not provide target buy prices or price alerts. However, our 9 active models produce fair value estimates ranging from $12.46 to $80.68. At $88.09, the stock trades above all model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.
Want the complete picture?
See all 13 model estimates, confidence scores, and the full valuation table for TMDX.
Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →
Buy with Gumroad